 LA JOLLA, Calif., Nov. 12, 2020 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that Principal Investigators Leila Gobejishvili, PhD and Craig McClain, MD at the University of Louisville School of Medicine presented positive results of the in-vitro and in-vivo studies that evaluated MN-001 tipelukast, referred to as D46 in the presentation for its anti-liver fibrotic effect in human hepatic stellate cells HSCs and in an acute liver injury model at the Liver Meeting Digital ExperienceTM 2020 TLMdXTM, the annual meeting of the American Association for the Study of Liver Diseases AASLD. 